COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

R&D Capabilities

We have an experienced team of over 80 scientists (with over 20 Ph.D.’s) dedicated to innovation in new product development, cost optimization, and novel route scouting projects. The R&D team develops novel/non-infringing process for APIs and is supported by a state-of-the-art, ‘best in class’, analytical research capabilities.

R & D capabilities include:

  • Development of environmental friendly processes
  • Development of chiral APIs
  • Ability to comply with ICH guidelines
  • Synthesis, Isolation and characterization of impurities
  • Expertise in handling pyrophoric reagent
  • Expertise in cryogenic reactions (-40 to -100°C)
  • Expertise in handling organometallic reactions

Locations

Our APIs are manufactured at US FDA approved sites across the globe- sites which have impeccable quality records: no warning letters or import alerts on any Piramal sites since inception of the company (1988 until today). On time readiness and delivery has been our strength through the combination of R&D innovation and fully integrated supply chain that levers the manufacture of intermediates in-house to help control cost and meet aggressive timelines. The API manufacturing sites are US FDA, UK MHRA, PMDA Japan, WHO GMP approved. The sites have API Regulatory submissions across the globe including e-CTD.

Shanghai, China - Sourcing Office Note: *Through PPS Minority Investment in Yapan Bio

Do you have a generic API development or manufacturing requirement?